Then the Fed began its tapering talk.
With the potential of rising interest rates on the table, investors have shunned high dividend paying sectors and shares of REITs have plunged in wake of the Fed�� news. Yet, given the commercial real estate sectors long term history of outperformance, investors looking for bargains may want to scoop up shares of operators of shopping plazas, office buildings and hospitals.
SEE: The REIT Way
Better Valuations
After reaching a six-year high set on May 21, 2013, REITs have plunged about 14.75% since the Federal Reserve provided an update regarding its plans for future bond purchases. However, investors may not want to cast off their commercial real estate holdings just yet in the face of the Fed�� taper talk. That�� because REITs continue to offer plenty of portfolio benefits- and time to buy hasn�� been better.
Hot Warren Buffett Stocks To Watch For 2015: Astellas Pharma Inc (ALPMY.PK)
Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, chronic hepatitis C, irritable bowel syndrome, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, agrypnia, atopic dermatitis and other diseases. Advisors' Opinion:- [By Henry Kawabe]
Seattle Genetic is currently collaborating on 22 different ADC drug trials in various stages of testing with twelve different pharmaceutical companies, including nine with Genentech (RHHBY.OB), two with AbbVie (ABBV), two with Agensys (ALPMY.PK), and one with Pfizer (PFE). To date, these ADC collaborations have generated more than $225 million for Seattle Genetics and have the potential to generate more than $3.5 billion in milestone payments plus royalties.
Hot High Dividend Companies To Own For 2014: Turkiye Garanti Bankasi AS (GARAN)
Turkiye Garanti Bankasi AS (the Bank) is a Turkey-based financial services company. The Bank provides retail, commercial, corporate and small and medium size enterprises (SME) banking, leasing, insurance, asset management and factoring services. Other operation heading under the banking segment include mainly treasury and investment banking activities as well as unallocated income and expense items. It has a network of 822 domestic branches, seven foreign branches, three representative offices abroad and 104 offices. In addition to its branches, the Bank has 100% ownership in three banks each of which is located in Amsterdam, Bucharest and Moscow. The Bank and its affiliates operate principally in Turkey, but also have operations in the Netherlands, Romania, Russia, Turkish Republic of Northern Cyprus, Malta, Luxembourg and Germany. Advisors' Opinion:- [By Halia Pavliva]
Turkiye Garanti (GARAN) Bankasi AS, the largest Turkish lender by market value, led gains on the Borsa Istanbul National 100 Index, which rose 1.5 percent. Garanti climbed 1.3 percent after slumping 4.1 percent to the lowest level since Sept. 13 yesterday. The government is selling $1.25 billion of five-year Islamic bonds today, according to a person with direct knowledge of the transaction, who asked not to be identified because the information is private.
- [By Julia Leite]
The Borsa Istanbul Stock Exchange National 100 Index climbed from a six-month low. Prime Minister Recep Tayyip Erdogan said he was ready to listen to the demands of anti-government protesters. The lira strengthened for the first time in three days and bonds gained. Lenders Turkiye Garanti Bankasi AS (GARAN) and Akbank T.A.S. added at least 3.2 percent.
- [By Ian Sayson]
Russia�� Micex Index declined, trimming its weekly gain to 2.5 percent. OAO Mechel, the nation�� biggest producer of coal for steelmakers, slumped 1.7 percent. The Borsa Istanbul National 100 Index sank 2 percent as Turkiye Garanti Bankasi AS (GARAN) led losses in lenders. Benchmark gauges in the Czech Republic and Hungary declined at least 1.2 percent.
Hot High Dividend Companies To Own For 2014: Rite Aid Corp (RAD)
Rite Aid Corporation, incorporated in 1968, is a retail drugstore chain in the United States. As of March 3, 2012, the Company operated drugstores in 31 states across the country and in the District of Columbia. As of March 3, 2012, it operated 4,667 stores. In the Company�� stores, it sells prescription drugs and a range of other merchandise, which it calls front end products. During the fiscal year ended March 3, 2012 (fiscal 2012), prescription drug sales accounted for 68.1% of its total sales. The Company carries a range of front end products, which accounted for 31.9% of its total sales in fiscal 2012. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchandise and other everyday and convenience products, as well as photo processing. It offers a variety of products under its private brands, which contributed approximately 17% of its front end sales in the categories where private brand products were offered in fiscal 2012. As of March 3, 2012, the Company had opened over 2,100 GNC stores-within-Rite Aid-stores. During fiscal 2012, the Company sold two owned operating stores to independent third parties.
During fiscal 2012, its stores filled approximately 295 million prescriptions and served an average of 2.1 million customers per day. The overall average size of each store in its chain is approximately 12,600 square feet. As of March 3, 2012, 60% of its stores were freestanding; 51% of its stores included a drive-thru pharmacy; 24% included one-hour photo shops, and 46% included a GNC store-within-Rite Aid-store. The Company�� customers may also order prescription refills over the Internet through www.riteaid.com, or over the phone through its telephonic automated refill systems for pick up at a Rite Aid store. It has a strategic alliance with GNC, a retailer of vitamin and mineral supplements.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Rite Aid (NYSE: RAD) shares shot up 12.99 percent to $7.23 after the company reported better-than-expected fiscal fourth-quarter net income. - [By Garrett Cook]
Rite Aid (NYSE: RAD) was down, falling 3.49 percent to $7.18 after the company reported a drop in its first-quarter earnings. Rite Aid’s quarterly profit declined to $41.4 million, or $0.04 per share, from a year-earlier profit of $89.7 million, or $0.09 per share.
- [By Jake L'Ecuyer]
Equities Trading UP
Rite Aid (NYSE: RAD) shot up 12.94 percent to $4.19 after the company posted a profit in its fiscal second quarter.Shares of GT Advanced Technologies (NASDAQ: GTAT) got a boost, shooting up 12.52 percent to $8.49. UBS upgraded the stock from Neutral to Buy.
- [By Michael Lewis]
Drug store chain Rite Aid (NYSE: RAD ) sailed to new highs this week as the company reported in its earnings release a return to annual profitability. The $2 billion company is trading up over 40% in the last year, and 60% since the beginning of 2013. The thing is, earnings did not show much to celebrate in the operating business, and its black bottom line was more the result of cost-cutting efforts and margin enhancement. At more than 20 times forward earnings, the market clearly is expecting some degree of sales growth down the line. Is this an accurate assumption, or should investors exercise caution?
Hot High Dividend Companies To Own For 2014: Diebold Inc (DBD)
Diebold, Incorporated, incorporated in August 1876, is engaged in providing integrated self-service delivery and security systems and services to the financial, commercial, government and retail markets. Sales of systems and equipment are made directly to customers by the Company�� sales personnel, manufacturers��representatives and distributors globally. The sales and support organizations work closely with customers and their consultants to analyze and fulfill the customers��needs. The Company has two lines of business: Self-Service Solutions and Security Solutions. The Company�� segments are consisted of two sales channels: Diebold North America (DNA) and Diebold International (DI). In September 2012, it acquired GAS Tecnologia (GAS).
The DNA segment sells and services financial and retail systems in the United States and Canada. The DI segment sells and services financial and retail systems over the remainder of the globe through wholly owned subsidiaries, joint ventures and independent distributors in countries throughout Europe, the Middle East, Africa, Latin America and in the Asia Pacific region, excluding Japan and Korea.
Self-Service Solutions
The Company offers an integrated line of self-service technologies and services, including comprehensive automated teller machine (ATM) outsourcing, ATM security, deposit and payment terminals and software. The Company is a global supplier of ATMs and related services. The Company offers a range of self-service solutions. Self-service products include a range of ATMs and teller automation, including deposit automation technology, such as check-cashing machines, bulk cash recyclers and bulk check deposit. The Company offers software solutions consisting of multiple applications, which process events and transactions. These solutions are delivered on the appropriate platform. From analysis and consulting to monitoring and repair, the Company provides value and support to its customers every step of the way. ! Services include installation and ongoing maintenance of its products, OpteView remote services, branch transformation and distribution channel consulting. Outsourced and managed services include remote monitoring, troubleshooting for self-service customers, transaction processing, currency management, maintenance services and full support through person to person or online communication.
Security Solutions
The Company provides its customers with the technological advances to protect their assets. The Company provides physical and electronic security systems, as well as facility transaction products, which integrate security, software and assisted-service transactions, providing total security systems solutions to financial, retail, commercial and government markets. The Company provides security solutions and facility products, including in-store bank branches, pneumatic tube systems for drive-up lanes, vaults, safes, depositories, bullet-resistive items and undercounter equipment. The Company provides a range of electronic security products, including digital surveillance, access control systems, biometric technologies, alarms and remote monitoring and diagnostics. The Company provides security monitoring solutions, including fire, managed access control, energy management, remote video management and storage, as well as logical security.
Integrated Solutions
The Company provides end-to-end outsourcing solutions with a single point of contact for customer�� self-service channel. Its solution includes hardware, software, services or a combination of all three components. The Company provides value to its customers by offering a range of integrated services and support. The Company�� service organization provides analysis and planning of new systems, systems integration, architectural engineering, consulting and project management, which encompass all facets of a financial self-service implementation. The Company also provides design, products, ser! vice, ins! tallation, project management and monitoring of electronic security products to financial, government, retail and commercial customers.
Election Systems
The Company is a provider of voting equipment and related products and services in Brazil. The Company provides elections equipment, networking, tabulation and diagnostic software development, training, support and maintenance.
The Company competes with NCR Corporation, Wincor-Nixdorf, Grg Equipment Co., Nautilus Hyosung, Itautec and Perto.
Advisors' Opinion:- [By Mark Morelli]
How will the potential disruption impact business and affect investors? Should the executives at ATM manufacturers such as Diebold (NYSE: DBD ) �be worried? Credit�and debit card processors like MasterCard (NYSE: MA ) and Visa (NYSE: V ) �are already benefiting from the trend to a cashless society. Could things get even better?
- [By Insider Monkey]
Security and services company Diebold (DBD) is simply a dividend beast. It has raised dividends in 60 consecutive years and currently offers a yield of 3.8%. Over the past three months, two insiders, CEO Andreas Mattes and VP John Kristoff, have bought Diebold stock. Mattes currently owns about $824K worth of the stock while Kristoff's position is a bit smaller, and in the entire year of 2013, Board members Rajesh Soin and Henry Wallace have also initiated purchases here.
- [By Rich Smith]
North Canton, Ohio-based Diebold (NYSE: DBD ) has a new CEO.
On Thursday, the manufacturer of "ATM" machines announced it has named Andy W. Mattes as the company's new president and chief executive officer. Mattes was chosen after a four-month search, and plucked from a position as senior vice president for global strategic partnerships at flash memory maker Violin Memory. He is keeping an advisory role at Violin, even as he takes over the top job at Diebold.
- [By Rich Smith]
Ohio-based Diebold (NYSE: DBD ) scored a win on Wednesday, when the company announced that North Carolina-based State Employees' Credit Union has hired it to upgrade more than 1,100 of SECU's automated teller machines to Diebold's Opteva configuration.
Hot High Dividend Companies To Own For 2014: Ziggo NV (ZIGGO)
Ziggo NV is the Netherlands-based provider of entertainment, information and communication through television, Internet and telephony services. The Company provides digital, interactive and high definition (HD) television, broadband Internet, data communication and telephony services to both private and corporate customers. To business customers, it offers services over the network. For home use and small business, they are provided through business bundles and packages, such as Office Basis, Internet Plus and All-in-1. Ziggo NV serves around 3 million households, with almost 1.8 million Internet subscribers, more than 2.2 million subscribers using digital television and about 1.4 million telephony subscribers. Additionally, it operates a music streaming service, Ziggo Muziek, and a fiber optic network. The Company is wholly owned by Zesko Holding BV and has several subsidiaries, such as Zesko BV, Ziggo Bond Company Holding BV and Ziggo Bond Company BV, among others. Advisors' Opinion:- [By Sarah Jones]
Ziggo NV (ZIGGO), a Dutch cable-television operator, advanced 4.5 percent to 29.58 euros, after Vodafone confirmed it approached Kabel Deutschland. Liberty Global Inc., which owns an 18 percent stake in Ziggo, had also considered bidding for the German company, two people familiar with the matter said in April.
Hot High Dividend Companies To Own For 2014: Ambit Biosciences Corp (AMBI)
Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Quizartinib
The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.
AC410
The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.
CSF1R Program
The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.
The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.
Advisors' Opinion:- [By Wallace Witkowski]
Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.
No comments:
Post a Comment